Ancillare Welcomes Jonathan Mishkin as Chief Financial Officer

Mishkin’s financial expertise strengthens Ancillare’s robust financial position and accelerates global expansion in the clinical supply chain industry.

Horsham, Pa. — April 27, 2023. Ancillare, LP, the global leader and only Life Sciences company dedicated to ancillary supply and equipment management for Phase I-IV clinical research, announces the appointment of Jonathan (Jon) Mishkin as Chief Financial Officer (CFO).

As CFO, Mishkin will be responsible for enabling and helping execute the company’s strategic aggressive growth initiatives, as well as financial strategy and execution, including budgeting, forecasting, and reporting. His expertise will support Ancillare’s ongoing commitment to delivering exceptional service and value to Sponsors in pharmaceutical, biotechnology, and CRO verticals.

Mishkin comes to Ancillare with an impressive background in finance, including financial analysis, strategic management, corporate finance, M&A, and international operations. With over two decades of hands-on experience, he has a proven track record of exceptional leadership and communication skills in working across departments and regions to achieve challenging business goals.

Before joining Ancillare, Mishkin was the CFO at Theradex Systems Inc., where he led a growing global Clinical Research Organization focused on oncology. He successfully implemented financial planning and analysis practices, consolidated global financial statements, and improved intercompany processes.

“Ancillare is known for its innovative approach and Jon’s financial acumen and international experience will be instrumental in driving our continued growth,” said Jason Monteleone, President. “We are thrilled to welcome him to our executive leadership team.”

Dr. Joanne Santomauro, Chief Executive Officer, said, “We believe Jon’s financial acumen coupled with Ancillare’s industry-leading model will create powerful ROI for our sponsors and the patients they serve. Adding Jon to the team moves us closer to achieving our aggressive growth goals and strengthens our position as a global leader in ancillary supply and equipment management for clinical research.”

Mishkin earned his Bachelor of Science in Finance from The Pennsylvania State University’s Smeal College of Business.

Ancillare Names Joshua Blacker Vice President of Global Business Development

Blacker brings two decades of experience and success as a performance-driven leader across the contract research organization (CRO) and biotechnology spaces.

Horsham, Pa. — February 2, 2023. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced the appointment of Joshua Blacker as Vice President of Global Business Development.

Blacker brings to Ancillare two decades of experience and success as a performance-driven leader, including business development and commercial operations across the contract research organization (CRO) and biotechnology spaces. He began his pharma career at Chiltern (previously Theorem Clinical Research), where he advanced to Executive Director, and served as head of the North America Oncology biotech business development team. Blacker next moved to Worldwide Clinical Trials, where he headed the strategic partnerships group. Most recently, he served as Senior Director of Business Development at OncoBay Clinical.

“Josh will be instrumental in driving the organization’s business development goals as well as building a high-performance sales organization,” said Jason Monteleone, President. “We’re excited to welcome Josh to our executive leadership team and look forward to his contributions to expand our global presence.”

As Vice President of Global Business Development, Blacker will set business development strategy and oversee execution. He will also lead Ancillare’s international sales team. Blacker will report directly to Monteleone.

“Josh has an exceptional track record of forging strategic partnerships and developing new relationships within the pharmaceutical, biotechnology, and CRO verticals,” said Dr. Joanne Santomauro, Chief Executive Officer. “Ancillare has aggressive growth objectives, and I am confident with Josh’s drive, deep industry ties, and knowledge of the market, he’ll help elevate Ancillare to new heights.”

Blacker holds a Bachelor of Business Administration in Finance from the University of San Francisco.

About Ancillare, LP

Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 8,000 clinical trials across 550,000 clinical sites in over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Australia, Brazil, Canada, China, India, Israel, Japan, Korea, Mexico, Philippines, Taiwan, Turkey, and United Kingdom. To learn more, visit Ancillare.com.

Ancillare Appoints Jason Monteleone as President

Monteleone, a recognized Life Sciences executive, will focus on new growth initiatives for the supply chain organization.

Horsham, Pa. — October 27, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, has appointed Jason Monteleone, MBA as its new President.

Monteleone joins Ancillare with over 25 years of experience in the healthcare, medical device, and life sciences industries. He most recently served as Chief Business and Strategy Officer at dMed-Clinipace — a global mid-sized CRO — and Chief Executive Officer at Clinipace prior to its 2021 merger with dMed. He presently serves as a Board Observer for the Drug Information Association (DIA), a global organization dedicated to uniting life sciences professionals across more than 80 countries to share insights and drive actions in healthcare product and life cycle management.

In prior years, Jason founded Pivotal Financial Consulting, a consultancy where he advised investors and companies in the clinical research sector, focused on acquisitions, growth and innovation. Jason was also Chief Financial Officer and Executive Vice President for Theorem Clinical Research – a global mid-sized Contract Research Organization acquired by Chiltern International in 2015.

“In my position at Ancillare, I look forward to pursuing growth strategies that will take this innovative organization to the next level,” Monteleone said. “Ancillare has solved a major pain point in clinical trial operations. In a fast-growing Clinical Trial Equipment and Ancillary Solutions market, it is poised to become the leading mid-sized global ancillary clinical supplies and logistics partner.”

As President, Monteleone will identify opportunities and strategies for the organization’s growth, applying expertise in sales, talent acquisition and development, and market expansion.

“Jason’s extensive experience serving the clinical research industry will be instrumental to Ancillare as we enter a new stage of growth,” said Dr. Joanne Santomauro, Chief Executive Officer. “We are excited to welcome him to the team. His expertise will embrace and enhance our goals to expand our global footprint, add new services, strengthen our partnerships, and deliver excellence to all our Sponsors.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 8,000 clinical trials across 550,000 clinical sites in over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, India, Israel, Japan, Korea, Philippines, Taiwan, Turkey, and United Kingdom. To learn more, visit Ancillare.com.

Ancillare Launches Employee Training and Development Program, Offers Tuition Assistance

Leading life sciences supply chain organization announces new professional development resources for its staff.

Horsham, Pa. — May 31, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, is proud to announce the official launch of Ancillare University, a set of professional development courses for its staff.

Ancillare University includes a variety of resources for professionals at all levels, including Leadership and Executive courses, preparation for Project Management Certifications, Technology training, and more. The program became available to employees earlier this year and is fully accessible to its remote-first workforce.

In addition to the educational resources it offers internally, Ancillare also offers a tuition assistance program for employees advancing their careers through higher education.

“Ancillare University is designed to help our employees build more fulfilling, growth-oriented careers,” said Dr. Joanne Santomauro, Chief Executive Officer. “As an organization built on innovation, it is highly important that we continue to invest in our workforce.”

Ancillare is currently hiring for a variety of roles in Project Management, Clinical Operations, Procurement, Technology, and more. To learn more about open positions and available benefits, visit Ancillare.com/Careers.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 8,000 clinical trials across 550,000 clinical sites in over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Joins Decentralized Trials & Research Alliance (DTRA)

Leading life sciences supply chain organization promotes adoption of decentralized clinical trials alongside fellow industry leaders.

Horsham, Pa. — February 8, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, announced today it has joined the Decentralized Trials & Research Alliance (DTRA), an historic alliance of over one hundred life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

The “Decentralized Trials & Research Alliance (DTRA),” which launched December 2020, is uniting industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

“Decentralized trials are the future of clinical research, and a well-managed supply chain is foundational to their success,” said Dr. Joanne Santomauro, Chief Executive Officer, Ancillare. “As a member of the DTRA, Ancillare will help pave the way to broader adoption of decentralized trials through awareness and innovation of the global Clinical Trial Ancillary Supply Chain.”

“We are extremely gratified to welcome Ancillare to the ‘Decentralized Trials & Research Alliance,’” said Amir Kalali, MD, founder of several collaborative life science communities, and co-Chair of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by Ancillare’s commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”

During the COVID-19 pandemic, Ancillare devoted greater focus to its Direct-to-Patient operation, which encompasses the assembly of ready-to-distribute single patient kits needed for decentralized research. The company is now expanding its facilities to accommodate enhanced kitting services for Sponsors conducting decentralized trials.

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, Ancillare is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-Chair, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”

To learn more about Ancillare’s work to advance clinical research through integrated supply chain strategies, visit Ancillare.com.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

About DTRA
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.

Ancillare Purchases Property Within U.S. Pharma Hub, Begins Facility Renovation

Industry leader in Clinical Trial Ancillary Supply Chain announces plans to upgrade its headquarters in time for the new year

Horsham, Pa. — November 9, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, recently announced its purchase of office and warehouse space at 700 Enterprise Road in Horsham, Pennsylvania.

Strategically located in Greater Philadelphia, the new property is the second location owned by Ancillare within the pharma corridor of the northeastern United States. The company plans to renovate the space to accommodate expansion of its core capabilities, including kitting, labeling, and Direct-to-Patient operations. Initial upgrades to the office and warehouse facilities will be completed this year.

“As a partner to a number of the top global pharmaceutical companies, we are proud to continue building our physical infrastructure here in the Philadelphia area,” said Dr. Joanne Santomauro, Chief Executive Officer. “We are hard at work developing specialty services to address the unique challenges of the pandemic and its indelible impact on the global CTASC.”

In addition to its United States presence, the organization has a vast Global Distribution Network spanning North and South America, Europe, and Asia-Pacific, including a second headquarters in the Netherlands. For the most up-to-date information on Ancillare’s expansion efforts, visit Ancillare.com.

About Ancillare, LP

Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.